127 related articles for article (PubMed ID: 20025095)
1. Injectable amphotericin B: mix-ups between lipid and non-lipid formulations.
Prescrire Int; 2009 Dec; 18(104):258-60. PubMed ID: 20025095
[TBL] [Abstract][Full Text] [Related]
2. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.
Mohr JF; Hall AC; Ericsson CD; Ostrosky-Zeichner L
Pharmacotherapy; 2005 Mar; 25(3):426-8. PubMed ID: 15843289
[TBL] [Abstract][Full Text] [Related]
3. ALERT: mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous.
Koczmara C; Richardson H; Hyland S; Lee CS; Hillebrand N
Dynamics; 2011; 22(1):24-6. PubMed ID: 21469498
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
5. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
6. [Amphotericin B: the end of an era].
Oude Lashof AM; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
8. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
9. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B use in children: conventional and lipid-based formulations.
Kuyucu N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):357-67. PubMed ID: 21417875
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B-deoxycholate overdose due to administration error in pediatric patients.
Groeneveld S; Verweij PE; Hek LV; Bökkerink JP; Warris A
Med Mycol; 2008 Mar; 46(2):185-7. PubMed ID: 18324499
[TBL] [Abstract][Full Text] [Related]
14. Acute amphotericin B overdose.
Burke D; Lal R; Finkel KW; Samuels J; Foringer JR
Ann Pharmacother; 2006 Dec; 40(12):2254-9. PubMed ID: 17090724
[TBL] [Abstract][Full Text] [Related]
15. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
16. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
18. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
19. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
20. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]